The Problem Schizophrenic : Clozapine or ECT? by Andrade, C.
LETTER TO EDITOR 
The Problem Schizophrenic: Clozapine or ECT? 
Sir, 
Clozapine was introduced in India with 
much fanfare in May 1995. Presently, there are 
three accepted indications for clozapine therapy: 
treatment resistant schizophrenia, intolerance to 
neuroleptic drugs and tardive dyskinesia (Marder 
and Van Putten, 1988). 
The pharmaceutical industry is a powerful 
lobby and it is therefore likely that clozapine will 
be enthusiastically used for these indications. 
Pressure will also come from families of patients 
who have been exposed to publicity about clozapine 
in the lay press. 
But is clozapine really the treatment meth-
od of choice for the indications specified? In 
view of the costs associated with clozapine ther-
apy and the unavoidable blood monitoring there-
by necessitated, and in view of the nearly 1% 
risk for agranulocytosis, I suggest not. 
Consider: the single most important report 
on which the present status of clozapine in 
psychopharmacology is based in the Kane et al. 
(1988) study which addressed rigorously defined 
treatment resistant schizophrenia. However, Kane 
et al. did not employ non-responsiveness to 
electroconvulsive therapy (ECT) in their defini-
tion of treatment resistance; social compulsions 
were no doubt responsible, for ECT is not a 
popular treatment in the USA. Infact, none of the 
published studies on clozapine recruited patients 
who fail a course of ECT. 
In India, no non-medical compulsions re-
strict the application of ECT to the treatment-
resistant schizophrenic. That ECT is effective in 
such patients is well known (Friedl, 1986: 
Gujavarty et al., 1987: Andrade, 1993) ECT, of 
course is also a convenient treatment for patients 
intolerant to neuroloptic drugs. And, ECT may 
also be therapeutic for tardive dyskinesia 
(Andrade, 1991). Finaly, there has been a resur-
gence of interest in maintenance ECT (Kellner, 
1994), and it is likely that continuation and main-
tenance (outpatient) ECT administered once in 2-
4 weeks may resolve the problem of mainte-
nance medication in such patients (Andrade, 
1995). 
ECT does not have a lobby to promote its 
optimal use: nevertheless, it is hoped that clini-
cians in India will consider ECT -
nonresponsiveness as an additional pre-requisite 
for patients who are to receive clozapine. 
C. Andrade 
Dept of Psychopharmacology 
NIMHANS, Bangalore 29. 
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